Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urinary frequency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Urinary frequency. Displaying page 5 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000906-36 Sponsor Protocol Number: GEB-IAL-2014-01 Start Date*: 2014-12-09
    Sponsor Name:Laboratorios Gebro Pharma S.A.
    Full Title: Randomized, parallel, multicenter, phase IV clinical trial to assess the efficacy of hyaluronic acid/chondroitin sulfate versus fosfomycin trometamol in recurrent urinary tract infection prevention.
    Medical condition: Recurrent urinary tract infections
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001081-80 Sponsor Protocol Number: NL22172 Start Date*: 2008-06-20
    Sponsor Name:Leiden University Medical Center
    Full Title: Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population with Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort...
    Medical condition: To determine whether a 7-day duration of antibiotic treatment is non inferior to 14-day standard duration of treatment in adults presenting at primary care or emergency department with febrile uri...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000507-44 Sponsor Protocol Number: D-FR-52120-223 Start Date*: 2016-06-29
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004126-24 Sponsor Protocol Number: DRI6271 Start Date*: 2007-12-12
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overac...
    Medical condition: Overactive bladder including urge urinary incontinence
    Disease: Version SOC Term Classification Code Term Level
    10.0 10059617 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) PT (Completed) FR (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003407-12 Sponsor Protocol Number: 191622-518 Start Date*: 2008-02-19
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin ...
    Medical condition: Neurogenic detrusor overactivity as a result of spinal cord injury, in patients with urinary incontinence, who have not been adequately managed with anticholinergic therapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002575-34 Sponsor Protocol Number: 19733 Start Date*: 2020-06-10
    Sponsor Name:Bayer AG
    Full Title: A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over ...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) PL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003372-73 Sponsor Protocol Number: ZTI-01-200 Start Date*: 2016-04-11
    Sponsor Name:Zavante Therapeutics, Inc.
    Full Title: A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, In...
    Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    19.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) LT (Completed) LV (Completed) SK (Completed) PL (Completed) EE (Completed) GR (Completed) BG (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002321-29 Sponsor Protocol Number: MK-7264-042 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence
    Medical condition: Chronic Cough and Stress Urinary Incontinence
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    20.0 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000477-21 Sponsor Protocol Number: 01579 Start Date*: 2017-03-27
    Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen
    Full Title: Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial
    Medical condition: uncomplicated urinary tract infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10046544 Urinary infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004590-28 Sponsor Protocol Number: 1207.5 Start Date*: 2005-04-06
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, pla...
    Medical condition: Patients aged 18-75 years, of both sexes with symptoms of overactive bladder syndrome for at least 6 months. Lower level term (LLT): Overactive bladder (10059617) System Organ Class: Renal and Uri...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003471-30 Sponsor Protocol Number: D-FR-52120-222 Start Date*: 2016-09-26
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) PT (Completed) CZ (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002214-14 Sponsor Protocol Number: IHO-0000-REN-0220-S Start Date*: 2022-12-19
    Sponsor Name:Klinikum rechts der Isar, Technische Universität München
    Full Title: Individualized homeopathy to reduce the use of antibiotics in women with recurring uncomplicated urinary tract infections
    Medical condition: Women with recurring uncomplicated urinary tract infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021872 Infection urinary tract LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004555-11 Sponsor Protocol Number: A0221009 Start Date*: 2008-01-23
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS AN "ADD-ON" THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS UNDER MONOTHERAPY ...
    Medical condition: overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) BE (Completed) NL (Completed) GR (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013089-26 Sponsor Protocol Number: 191622-096 Start Date*: 2009-09-16
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder with Urinary Incont...
    Medical condition: Patients with symptoms of idiopathic overactive bladder (frequency and urgency)with urinary incontinence, whose symptoms have not been adequately managed with anticholinergic therapy.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002625-11 Sponsor Protocol Number: MO29983 Start Date*: 2016-12-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT
    Medical condition: Advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) EE (Completed) LT (Completed) DE (Completed) HU (Completed) IE (Completed) DK (Completed) CZ (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BG (Completed) NL (Completed) PL (Completed) ES (Completed) BE (Completed) SK (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015817-31 Sponsor Protocol Number: OC3-DB-02 Start Date*: 2009-12-01
    Sponsor Name:OxThera IP AB
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004281-17 Sponsor Protocol Number: 191622-517 Start Date*: 2007-12-18
    Sponsor Name:Allergan Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Com...
    Medical condition: Patients with lower urinary tract symptoms due to Benign Prostatic Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) IT (Completed) GB (Completed) CZ (Completed) AT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-004124-23 Sponsor Protocol Number: A0221058 Start Date*: 2009-01-29
    Sponsor Name:Pfizer Limited
    Full Title: A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder
    Medical condition: Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001463-64 Sponsor Protocol Number: CA183-001 Start Date*: 2005-07-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Revised Protocol #01, version 2.0 incorporating ...
    Medical condition: Advanced Cancer, IV, Nos
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000475-16 Sponsor Protocol Number: 2006-001-Oxy-OAB-Skin-Oxy Start Date*: 2007-04-12
    Sponsor Name:Johannes Gutenberg-Universität Mainz, Urologische Klinik (ausführende Stelle), Prof. Dr. med. Thürof
    Full Title: Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients
    Medical condition: •Male or female (18 – 80 years) suffering from OAB. •Symptoms of OAB as defined by: Urgency frequency ≥7 /week,•Urinary urgency incontinence (≥ 7 UIE/week),•Urodynamically proven detrusor instability
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 13:32:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA